News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts. WEEKLY
Cleaning Verification: Method Development and Validation Using Ion Mobility Spectrometry
The authors discuss the theory of ion mobility spectrometry, its benefit over HPLC analysis in cleaning verification, and the experimental considerations for method validation and validation.
The cleanliness of manufacturing and packaging equipment in the pharmaceutical industry is critical to ensure product efficacy,
personal safety, and the absence of unwanted active pharmaceutical ingredient (API) before the introduction of a different
compound. Upon completion of processing a drug substance or tablet formulation, a detergent cleans each part of the pharmaceutical
equipment.
The cleaning verification process in the pharmaceutical industry involves several steps. First, the clinical supply or manufacturing
unit of a company submits samples for analysis following the equipment cleaning process. The sample analysis is completed
by an analytical department or quality control (QC) personnel. The results are reported back to the clinical supply unit,
and the process is repeated until all samples have met the acceptable residual limit (ARL). The subject exposure limit (SEL)
(in units of mg/subject/day) for a given compound is provided by a drug-safety evaluation group and is an industry-wide practice.
The ARL of the API in each swab sample is a set at one-tenth of the SEL.
These types of samples have been analyzed by high-performance liquid chromatography (HPLC). In an effort to significantly
reduce sample turnaround time, which can take as long as several days, ion mobility spectrometry (IMS) has been evaluated
as an alternative method for analysis (1–4). The time taken for analysis is important because the faster that cleaning can
be confirmed, the faster the plant can return to operation. This article discusses the theory of IMS, the benefit of IMS over
HPLC analysis, and experimental considerations for method development and validation.
Theory
Figure 1: The IonScan-LS ion mobility spectometer with the Cobra autosampler.(FIGURES COURTESY OF THE AUTHORS)
IMS is a type of separation technique, similar to time-of-flight mass spectrometry, that distinguishes ions of a given compound
based on their velocities through a drift tube under the influence of a weak electric field. The technique characterizes chemical
substances based on their gas-phase ion mobilities and provides detection and quantitation of trace analytes (1). There are
several IMS instrument vendors. Figure 1 shows the IonScan-LS ion mobility spectrometer with the Cobra autosampler (Smiths
Detection, Warren, NJ), which was used in the studies described in this article.
Figure 2: Cross-sectional view of the ion mobility spectrometer sample inlet, ionization chamber, drift tube, and detector.
To perform the IMS analysis, a sample solution containing a compound of interest is injected by the autosampler onto a PTFE
substrate and allowed to dry. Figure 2 shows the sample inlet, ionization chamber, drift tube, and detector (5). Sample is
introduced by heating the substrate to ~290 °C, which results in desorption or vaporization of the sample into an inlet tube.
Primary ion formation occurs through atmospheric pressure chemical ionization (APCI) using nickel-63 as the radioactive source.
Following many collisions, product ions are formed and gated into the drift tube. These ions-based on size, shape, and charge-travel
through the drift tube toward the detector at different velocities. In contrast to mass spectrometers, separation of ions
is based on a size–charge relationship rather than the mass–charge ratio (6).
Elizabeth Galella is a research scientist at the analytical research and development unit of the Pharmaceutical Research Institute, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, NJ 08903.
Articles by Elizabeth Galella
Scott Jennings
Scott Jennings is a senior research scientist at the analytical research and development unit of the Pharmaceutical Research Institute, Bristol-Myers Squibb.
Articles by Scott Jennings
Madhavi Srikoti
Madhavi Srikoti is an associate research scientist at the analytical research and development unit of the Pharmaceutical Research Institute, Bristol-Myers Squibb.
Articles by Madhavi Srikoti
Elizabeth Bonasso
Elizabeth Bonasso is a research scientist at the analytical research and development unit of the Pharmaceutical Research Institute, Bristol-Myers Squibb.
Articles by Elizabeth Bonasso
Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
